Baker Tilly Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,931
| Closed | -$398K | – | 565 |
|
|
2023
Q1 | $398K | Sell |
3,931
-156
| -4% | -$15.8K | 0.04% | 392 |
|
|
2022
Q4 | $488K | Sell |
4,087
-1,118
| -21% | -$134K | 0.06% | 329 |
|
|
2022
Q3 | $553K | Sell |
5,205
-246
| -5% | -$26.1K | 0.08% | 270 |
|
|
2022
Q2 | $531K | Sell |
5,451
-434
| -7% | -$42.3K | 0.07% | 286 |
|
|
2022
Q1 | $552K | Buy |
5,885
+2,057
| +54% | +$193K | 0.06% | 323 |
|
|
2021
Q4 | $326K | Sell |
3,828
-460
| -11% | -$39.2K | 0.04% | 422 |
|
|
2021
Q3 | $411K | Buy |
4,288
+1,335
| +45% | +$128K | 0.05% | 361 |
|
|
2021
Q2 | $287K | Buy |
2,953
+864
| +41% | +$84K | 0.05% | 408 |
|
|
2021
Q1 | $203K | Buy |
+2,089
| New | +$203K | 0.04% | 446 |
|